Bio Pharma Dive
DECEMBER 10, 2023
A new sickle cell disease therapy developed by CRISPR Therapeutics and Vertex Pharmaceuticals is now approved in the U.S. and U.K. This is the story of how it came to be.
Pharmaceutical Technology
DECEMBER 10, 2023
Access and buy GlobalData’s databook on the latest filings and grants activity for CSL here.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
DECEMBER 10, 2023
While new gene therapies for the blood disease grabbed headlines at ASH, Pfizer presented fresh data for an oral drug meant to build on its marketed therapy Oxbryta.
Pharmaceutical Technology
DECEMBER 10, 2023
Access and buy GlobalData’s databook on the latest filings and grants activity for CSL here.
Drug Patent Watch
DECEMBER 10, 2023
In the ever-evolving landscape of the biotech and pharmaceutical sectors, accurate valuation of post-revenue drug assets stands as the linchpin for informed and strategic decision-making. The significance of this valuation… The post Decoding Pfizer’s Portfolio: A New Model for Precision in Pharma Investments appeared first on DrugPatentWatch - Make Better Decisions.
JAMA Internal Medicine
DECEMBER 10, 2023
This cohort study examines the association of periconceptional use of glucagon-like peptide 1 (GLP-1) receptor agonists or other noninsulin second-line antidiabetic medications with increased risk of major congenital malformations.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Fierce Pharma
DECEMBER 10, 2023
Roche’s blood cancer portfolio is booming with new life thanks to the antibody-drug conjugate Polivy and bispecifics. | As Roche’s blood cancer portfolio booms with new life thanks to the antibody-drug conjugate Polivy and bispecifics, the company is offering a look at data for two combinations of those drugs that support two phase 3 trials in diffuse large B-cell lymphoma.
Pharmaceutical Technology
DECEMBER 10, 2023
Access and buy GlobalData’s databook on the latest filings and grants activity for United Laboratories International here.
Roots Analysis
DECEMBER 10, 2023
ResMed has sold millions of magnetic CPAP masks since 2014 and received only five reports of serious harm related to the magnets, which were reported to authorities. Introduction to Magnetic CPAP Masks The medical devices domain is facing a wave of safety concerns as ResMed, a prominent manufacturer of continuous positive airway pressure (CPAP) machines, issues an urgent field safety notice regarding its magnetic masks.
Pharmaceutical Technology
DECEMBER 10, 2023
Access and buy GlobalData’s databook on the latest filings and grants activity for Sun Pharmaceutical Industries here.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Roots Analysis
DECEMBER 10, 2023
Introduction In the ever-evolving landscape of weight loss solutions, keto gummies and weight loss gummies have emerged as tantalizing options, promising to revolutionize the journey to a healthier, slimmer self. As the hype around these supplements continues to build, the pressing questions on everyone’s minds are: Do they really work, and are they safe?
Pharmaceutical Technology
DECEMBER 10, 2023
Access and buy GlobalData’s databook on the latest filings and grants activity for Sun Pharmaceutical Industries here.
Roots Analysis
DECEMBER 10, 2023
Introduction In the ever-evolving landscape of medical advancements, a groundbreaking study conducted by Resonant, a Utah-based biotech company specializing in diagnostic tests for neurodegenerative diseases, is developing an Alzheimer’s blood test, a potential game-changer in the early detection of Alzheimer’s disease. The research suggests that a simple blood test could be the key to identifying Alzheimer’s several years before symptoms surface, offering a glimmer of hope for milli
Pharmaceutical Technology
DECEMBER 10, 2023
Access and buy GlobalData’s databook on the latest filings and grants activity for Hisamitsu Pharmaceutical here.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Roots Analysis
DECEMBER 10, 2023
Aya Healthcare strengthens its physician recruitment technology by acquiring Winnow AI, a move aimed at boosting its capabilities in the digital staffing sector. In a significant move poised to revolutionize healthcare recruitment, Aya Healthcare, a leading healthcare staffing and workforce solutions provider, has successfully acquired Winnow AI. The acquisition marks a strategic partnership between Aya Healthcare and SwitchPoint Ventures, the creator of Winnow AI, an innovative artificial intel
Pharmaceutical Technology
DECEMBER 10, 2023
Access and buy GlobalData’s databook on the latest filings and grants activity for Hisamitsu Pharmaceutical here.
JAMA Internal Medicine
DECEMBER 10, 2023
This case report describes a patient in their 50s who collapsed, received chest compressions, and recovered consciousness at home.
Pharmaceutical Technology
DECEMBER 10, 2023
Access and buy GlobalData’s databook on the latest filings and grants activity for Cosmo Pharmaceuticals here.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Drug Patent Watch
DECEMBER 10, 2023
Five years of exclusivity is provided for drugs which do not contain active molecules that have appeared in previously-approved drugs. This is one of the longest exclusivity terms provided by… The post Pharmaceutical companies with the most ‘New Chemical Entity’ drugs appeared first on DrugPatentWatch - Make Better Decisions.
Pharmaceutical Technology
DECEMBER 10, 2023
Access and buy GlobalData’s databook on the latest filings and grants activity for Cosmo Pharmaceuticals here.
Roots Analysis
DECEMBER 10, 2023
Novo Nordisk aims to employ insights from obesity drug research to proactively hinder the occurrence of weight gain. Introduction Novo Nordisk, the eminent Danish pharmaceutical giant, has embarked on a groundbreaking journey. While the demand for Novo Nordisk’s weight-loss and diabetes drugs has already propelled the company to the status of Europe’s largest, it now seeks to revolutionize the paradigm by preventing weight gain itself.
Pharmaceutical Technology
DECEMBER 10, 2023
Access and buy GlobalData’s databook on the latest filings and grants activity for Daewoong here.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Pharmaceutical Technology
DECEMBER 10, 2023
Access and buy GlobalData’s databook on the latest filings and grants activity for Almirall here.
Pharmaceutical Technology
DECEMBER 10, 2023
Access and buy GlobalData’s databook on the latest filings and grants activity for Daewoong here.
Pharmaceutical Technology
DECEMBER 10, 2023
Access and buy GlobalData’s databook on the latest filings and grants activity for Almirall here.
Pharmaceutical Technology
DECEMBER 10, 2023
Access and buy GlobalData’s databook on the latest filings and grants activity for Otsuka here.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharmaceutical Technology
DECEMBER 10, 2023
Access and buy GlobalData’s databook on the latest filings and grants activity for Otsuka here.
Pharmaceutical Technology
DECEMBER 10, 2023
Access and buy GlobalData’s databook on the latest filings and grants activity for Lupin here.
Pharmaceutical Technology
DECEMBER 10, 2023
Access and buy GlobalData’s databook on the latest filings and grants activity for Cipla here.
Pharmaceutical Technology
DECEMBER 10, 2023
Access and buy GlobalData’s databook on the latest filings and grants activity for Lupin here.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
356 
Let's personalize your content